New Haven-based Achillion Pharmaceuticals Inc. said today it received a U.S. patent on a treatment agent used against hepatitis C.
U.S. Patent No. 7,476,686 for the Achillion antagonist that targets a key protein in the hepatitis C virus and prevents it from replicating expires in 2025.
Achillion CEO Michael D. Kishbauch said the company, working with Gilead Sciences, based in Foster City, Calif., hopes to begin using the anti-agent in human clinical trials later this year.
At 11 a.m., Achillion traded at $1.73, up 10 cents, or 6 percent.
